Perspective Therapeutics Inc
CATX
Get informed when a big investor buys or sells
+ FollowMarket Cap$304.37M
Close$
$0.39
87.9% downside
Current Fair Value
87.9% downsideOvervalued by 87.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $304.37 Million |
|---|---|
| Enterprise Value | $279.61 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.4 |
| Beta | 1.76 |
| Outstanding Shares | 103,604,000 |
Return
| Return on Equity | -37.36% |
|---|---|
| Return on Assets | -31.60% |
| Return on Invested Capital | -25.01% |
Valuation & Multiples
| P/E Ratio | -3.67 |
|---|---|
| PEG | -8.33 |
| Price to Sales | - |
| Price to Book Ratio | 1.08 |
| Enterprise Value to Revenue | 538.76 |
| Enterprise Value to EBIT | -2.95 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.1 |
| Debt to Equity | 0.08 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 12, 2026
EPS Estimate
$-0.29
Average shareholder expectationRevenue Estimate
$157,381
Average shareholder expectationNext Earnings Call
Expected Date
August 12, 2026
EPS Estimate
$-0.27
Average shareholder expectationRevenue Estimate
$90,528
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Perspective Therapeutics Inc
64 employees
CEO: Lori Woods Isoray, Inc., through its subsidiary, Isoray Medical, Inc., is the sole producer of Cesium Blu brachytherapy seeds, which are expanding brachytherapy treatment options throughout the body.